Clinical Trials
97
Active:0
Completed:93
Trial Phases
4 Phases
Phase 1:66
Phase 3:27
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (96 trials with phase data)• Click on a phase to view related trials
Phase 1
66 (68.8%)Phase 3
27 (28.1%)Not Applicable
2 (2.1%)Phase 4
1 (1.0%)A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Phase 3
Completed
- Conditions
- Rosacea
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 1105
- Registration Number
- NCT03954444
- Locations
- 🇺🇸
Site 1, Lynchburg, Virginia, United States
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo pressurized metered dose inhaler
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 1902
- Registration Number
- NCT03879837
- Locations
- 🇺🇸
Site 1, Spartanburg, South Carolina, United States
Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo Inhalation Powder
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 999
- Registration Number
- NCT03756883
- Locations
- 🇺🇸
Study Site 101, Miami Lakes, Florida, United States
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
Phase 3
Completed
- Conditions
- Cataract
- Interventions
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 448
- Registration Number
- NCT03499873
- Locations
- 🇺🇸
Key-Whitman Eye Center, Dallas, Texas, United States
Clinical Endpoint Study of Ivermectin 0.5% Lotion
Phase 3
Completed
- Conditions
- Head Lice
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 905
- Registration Number
- NCT03301649
- Locations
- 🇺🇸
Site 1, Miami, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
No news found